All News

Article

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Dr. John Cush Tweet
RheumNow
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/h0oe3WksK1
Dr. John Cush Tweet
RheumNow
Systematic review of live virus MMR in #JIA had 9 studies (743 pts) showing no flares, good safety & immunogenicity in short term, BUT incomplete or less durable protection in biologic-treated patients, especially for measles & rubella. 5-yrs post MMR, seroprotection was lower if https://t.co/JQhL9o1O4e
Dr. John Cush Tweet
RheumNow
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/7HUqGGBeJ8
Dr. John Cush Tweet
RheumNow
Single center study of 102 pts starting JAK inhibitor (72% >50yrs; 77% RA) shows only 27.5% received at least one RZV vaccination dose (Shingrix) & only 3 recv RZV within 30 daysof a JAK inhibitor. ????? (I vaccinate everyone going on a JAKi w/ Shingrix - don't you?) https://t.co/j2jrBIiuOo
Dr. John Cush Tweet
RheumNow
TMP-SMX prophylaxis cuts PJP risk by 69% (RR 0.31) & mortality by 59% (RR 0.41) in immunosuppressed rheum dz pts —but ADRs are 26x more common. NNT=323, NNH=5. Risk-adapted approach recommended. #EULAR2026 POS1190 https://t.co/4yjD9CmySM
Jiha Lee Tweet
JihaRheum
#EULAR2026 Recommendations: Immunization (new since 2011) - Vaccinate early regardless of dz acitiviry - HBV booster/passive if poor response - Yellow fever may be considered on individual basis - Avoid live vaccines (mostly) in newborn exposed in utero to biologic @RheumNow
Janet Pope Tweet
Janetbirdope
Controversial #Rheumatoid #arthritis disease activity May not affect #ILD BUT affects #mortality level evidence +/- PHillippe Dieude said #Rx from RCTs #IS Ex #rituximab #antifibrotics #nintedanib #nerandomilast HOw to Treat RA-ILD June 5 #EULAR2026 @RheumNow @eular_ARD https://t.co/R60nX6XzL8
Mrinalini Dey Tweet
DrMiniDey
#OP0340 Long-term DARALUP data suggest CD38-targeting with daratumumab may be promising in refractory SLE, with rapid serologic and clinical improvements sustained to 84 weeks in many patients. Flares occurred in 6/10 patients but responded to belimumab. #EULAR2026 @RheumNow
Bella Mehta Tweet
bella_mehta
Post marketing safety signals of anifrolumab from US FDA adverse event reporting system - herpes zoster significantly associated. Others include infusion reactions and intermittent hypersensitivity @RheumNow ##EULAR2026 #POS1067
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×